What is the rationale for treating early RRRM with targeted therapies?

The Multiple Myeloma Hub spoke to Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What is the rationale for treating early relapsed/refractory multiple myeloma (RRMM) with targeted therapies?

In this interview, Lonial discusses how the treatment landscape for early RRMM has changed over time, impacting the effectiveness of standard of care therapies and leading to an increased interest in new targeted approaches, such as CAR T-cell therapies, bispecific antibodies, and antibody–drug conjugates. Lonial outlines the latest regulatory updates and available options for patients who are ineligible for or unable to access all advanced therapies.

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.